Silo Pharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics and drug delivery systems for traditional and psychedelic medicines. Its core products include SPC-15, an intranasal 5-HT(4) receptor agonist formulation aimed at treating post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; SP-26, a ketamine-based time-release injectable implant for chronic pain and fibromyalgia; SPC-14, an intranasal compound in preclinical development for Alzheimer's disease; and SPU-16, a central nervous system homing peptide targeting multiple sclerosis and other neurological disorders. The company develops these innovative treatments with proprietary formulations designed to improve delivery and efficacy, and it collaborates with academic institutions and independent laboratories for research and development. Silo Pharma operates primarily in the United States and is headquartered in Englewood Cliffs, New Jersey. Recent major developments include the expansion of its intellectual property portfolio with a patent application for SPC-14, exclusively licensed from Columbia University; the advancement of SPC-15 toward a planned IND submission in 2025 with encouraging preclinical toxicology and pharmacokinetics data; completion of a drug-device study for SPC-15's microchip-based nasal spray delivery system; and positive large-animal safety results. The company has also entered into strategic partnerships, including a development agreement with Sever Pharma for ketamine implant therapeutics, and collaboration with a global CRO for CNS-targeting peptides. In addition to its biopharma activities, Silo Pharma launched a digital assets treasury program, acquiring Ethereum and Solana cryptocurrencies as part of a strategy to bolster its financial position. Recently, it closed a $2.5 million registered direct offering to support working capital and corporate purposes. Founded in 2011, Silo Pharma targets underserved conditions in neuropsychiatry and neurology, including PTSD, chronic pain, Alzheimer's disease, and multiple sclerosis. Its portfolio combines traditional psychotropic agents and psychedelics with novel drug delivery systems, focusing on expedited regulatory pathways such as the FDA's 505(b)(2) streamlined approval process. The company continues to advance its clinical pipeline while leveraging innovative funding and strategic alliances to support growth and product development.
Company News
Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
InterCure (NASDAQ:INCR) & Silo Pharma (NASDAQ:SILO) Financial Review
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Expands By 795.6%
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury